Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen while preserving the attenuation of the parental virus strain.
Thymidine kinase-negative recombinant vaccinia virus LC16m0 or LC16m8 expressing hepatitis B surface antigen preserved almost the same pathogenicity as their parental thymidine kinase-positive attenuated virus strains. The results demonstrate the potential for using the LC16m0 or LC16m8 virus strain as a vector for recombinant vaccine.
D000818:Animals; D000941:Antigens; D001921:Brain / Q000382:microbiology* / Q000473:pathology; D005455:Fluorescent Antibody Technique; D005814:Genes, Viral; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D008587:Meningitis, Viral / Q000382:microbiology; D051379:Mice; D011817:Rabbits; D013937:Thymidine Kinase / Q000235:genetics / Q000378:metabolism; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014616:Vaccinia virus / Q000201:enzymology / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity*; D014774:Virulence
D000941:Antigens; D006514:Hepatitis B Surface Antigens; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D013937:Thymidine Kinase